CYP11A1 inhibition as a therapeutic approach for the treatment of castration resistant prostate cancer.

被引：3
|
作者：
Oksala, Riikka
Karimaa, Mari
Simola, Outi
Ramela, Meri
Riikonen, Reetta
Vehmaan-Kreula, Pirjo
Rummakko, Petteri
Wohlfahrt, Gerd
Kallio, Pekka
Mustonen, Mika V. J.
机构：
[1] Orion Corp Orion Pharma, Turku, Finland
[2] Orion Corp Orion Pharma, Espoo, Finland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 06期
关键词：
D O I：
10.1200/JCO.2018.36.6_suppl.340
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
340
引用
收藏
页数：1
相关论文
共 50 条
  • [11] DHODH inhibition represents a therapeutic strategy and improves abiraterone treatment in castration-resistant prostate cancer
    Guo, Shaoqiang
    Miao, Miaomiao
    Wu, Yufeng
    Pan, Dongyue
    Wu, Qinyan
    Kang, Zhanfang
    Zeng, Jianwen
    Zhong, Guoping
    Liu, Chengfei
    Wang, Junjian
    ONCOGENE, 2024, 43 (19) : 1399 - 1410
  • [12] DHODH inhibition represents a therapeutic strategy and improves abiraterone treatment in castration-resistant prostate cancer
    Shaoqiang Guo
    Miaomiao Miao
    Yufeng Wu
    Dongyue Pan
    Qinyan Wu
    Zhanfang Kang
    Jianwen Zeng
    Guoping Zhong
    Chengfei Liu
    Junjian Wang
    Oncogene, 2024, 43 : 1399 - 1410
  • [13] Metastatic castration-resistant prostate cancer. Part 1: the challenges of the disease and its treatment
    Bahl, Amit
    EUROPEAN JOURNAL OF ONCOLOGY NURSING, 2013, 17 : S1 - S6
  • [14] Novel therapeutic approaches for the treatment of castration-resistant prostate cancer
    Heidegger, Isabel
    Massoner, Petra
    Eder, Iris E.
    Pircher, Andreas
    Pichler, Renate
    Aigner, Friedrich
    Bektic, Jasmin
    Horninger, Wolfgang
    Klocker, Helmut
    JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2013, 138 : 248 - 256
  • [15] Castration-resistant prostate cancer. Surgical and radio-oncological therapeutic options
    Preusser, S.
    Putora, P. M.
    Plasswilm, L.
    Schmid, H. P.
    UROLOGE, 2012, 51 (01): : 27 - 31
  • [16] The effect of PARP inhibition on androgen receptor localization and activity in castration resistant prostate cancer.
    Nizialek, Emily
    Haffner, Michael
    Bhamidipati, Akshay
    Yegnasubramanian, Srinivasan
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E17037 - E17037
  • [17] CYP17A1 inhibitors in castration-resistant prostate cancer
    Gomez, Lissette
    Kovac, Jason R.
    Lamb, Dolores J.
    STEROIDS, 2015, 95 : 80 - 87
  • [18] Prospective evaluation of neuromediators during treatment with docetaxel in castration resistant prostate cancer.
    von Hardenberg, Jost
    Schwartz, Maike
    Bolenz, Christian
    Weiss, Christel
    Werner, Thorsten
    Fuxius, Stefan
    Mueller, Markus
    Frangenheim, Thomas
    Heinrich, Elmar
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [19] New Therapies for Castration-Resistant Prostate Cancer.
    Longo, Dan L.
    NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (05): : 479 - 481
  • [20] The plasma lipidome in castration-resistant prostate cancer.
    Horvath, Lisa
    Lin, Hui-Ming
    Mahon, Kate Lynette
    Weir, Jacquelyn
    Mundra, Piyushkumar
    Spielman, Calan
    Briscoe, Karen P.
    Gurney, Howard
    Mallesara, Girish
    Marx, Gavin M.
    Stockler, Martin R.
    Parton, Robert
    Hoy, Andrew
    Daly, Roger J.
    Meikle, Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345